|
EP2545907A1
|
|
Aqueous wet granulation process for cross-linked polyallylamine polymers
|
|
ES2390774A1
|
|
Kit that includes a multi-chamber container
|
|
EP2499913A1
|
|
Antiseptic solutions comprising chlorhexidine or its salt and an anionic dye and their preparation
|
|
EP2409699A1
|
|
Stable compositions of voriconazole
|
|
WO2010149794A2
|
|
Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane)
|
|
EP2388008A1
|
|
Stable, preservative-free, aqueous formulation for the administration by aerosolization comprising tobramycin
|
|
EP2363111A1
|
|
Stable pharmaceutical composition comprising bisphosphonate
|
|
WO2010007164A1
|
|
Method of assaying an aminoadamantane derivative
|
|
ES2350999A1
|
|
NEW PHARMACEUTICAL COMPOSITION UNDERSTANDING POLY HYDROCHLORIDE (ALILAMIN-CO-N, N'-DIALIL-1,3-DIAMINO-2-PROPANE HYDROXY).
|
|
WO2009031026A2
|
|
Lamivudine-cyclodextrin complex
|
|
WO2009066181A2
|
|
Oral delayed-release duloxentine hydrochloride pellets
|
|
WO2009081283A2
|
|
Aqueous formulations of acetaminophen for injection
|
|
WO2009047634A2
|
|
Aqueous formulations of acetaminophen for injection
|
|
WO2009001163A1
|
|
Lyophilized preparations of pantoprazole sodium for injection
|
|
US2010034885A1
|
|
Formulations containing glimepiride and/or its salts
|
|
US2009215756A1
|
|
Formulations containing losartan and/or its salts
|
|
WO2007029124A2
|
|
Formulations containing pantoprazole free acid and its salts
|
|
ES2288117A1
|
|
SOLID PHARMACEUTICAL COMPOSITION OF GABAPENTINA.
|
|
ES2279707A1
|
|
ORAL FORMULATIONS THAT INCLUDE 3'-AZIDONUCLEOSIDS.
|
